Skip to main content
    C

    Cerus Corporation (CERS)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $1.86
    -0.12 (-6.30%)

    Market Cap: $400.88M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Cerus Corporation (CERS) Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Cerus (CERS) trades at 1.6x sales and 5.0x book value. Its P/S of 1.6x is below its 5-year median of 2.0x.

    Current Multiples

    Its enterprise value is 284.0x its EBITDA. Its free cash flow yield is 0.1%.

    MultipleValue
    P/E (trailing)N/A
    Forward P/EN/A
    Price to sales1.6x
    Price to book5.0x
    EV/EBITDA284.0x
    Price to FCF759.3x
    EV/FCF854.4x
    PEGN/A
    FCF yield0.1%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/S is 73.3% below 6.0x and its P/B is 42.5% below 8.7x.

    MultipleCurrent5-year median10-year median
    P/S1.6x2.0x6.0x
    P/B5.0x6.8x8.7x
    Medians of month-end values through Oct 2026: 60 months (5-year) and 120 months (10-year).

    Valuation History

    Over the 10 year ends shown, its P/S ranged from 1.4x in 2024 to 11.3x in 2016.

    Year endPriceP/SP/B
    2025$2.061.8x6.2x
    2024$1.541.4x5.1x
    2023$2.162.1x7.4x
    2022$3.653.4x9.6x
    2021$6.817.3x13.9x
    2020$6.929.9x11.2x
    2019$4.226.3x10.6x
    2018$5.078.8x8.2x
    2017$3.387.2x9.9x
    2016$4.3511.3x7.8x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported.

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About CERS

    Is CERS stock overvalued?

    GNG's valuation label for CERS is Undervalued.

    What is CERS's price to sales ratio?

    Cerus has a price to sales ratio of 1.6x.